Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
Real-time Euronext Paris  -  12:35:20 2023-03-24 pm EDT
301.70 EUR   +0.40%
03/17Good timing to go long again
MS
03/14CORRECTION/Sartorius reduces staff at headquarters in Göttingen
DP
03/14Hiring freeze and voluntary redundancies at laboratory supplier Sartorius
DP
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius Stedim Biotech : Good timing to go long again

03/17/2023 | 02:25am EDT
long trade
Live
Entry price : 306.6€ | Target : 350€ | Stop-loss : 280€ | Potential : 14.16%
The recent downward movement has sent Sartorius Stedim Biotech shares back to attractive levels situated around 288.3 EUR. This zone could put an end to the downward movement and offers a good timing for new long positions.
Investors have an opportunity to buy the stock and target the € 350.
Sartorius Stedim Biotech : Sartorius Stedim Biotech : Good timing to go long again
Summary
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

  • Weaknesses
    • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.56 times its estimated earnings per share for the ongoing year.
    • The company's "enterprise value to sales" ratio is among the highest in the world.
    • The company appears highly valued given the size of its balance sheet.
    • The valuation of the company is particularly high given the cash flows generated by its activity.
    • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
    • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
    • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
    • For the last few months, analysts have been revising downwards their earnings forecast.
    • Over the past four months, analysts' average price target has been revised downwards significantly.
    • The group usually releases earnings worse than estimated.
    Ratings chart
    Subsector Other Medical Equipment, Supplies & Distribution
    1st jan.Capitalization (M$)Investor Rating
    SARTORIUS STEDIM BIOTECH-0.26%29 911
    ABBOTT LABORATORIES-10.69%170 406
    MEDTRONIC PLC2.12%105 596
    BECTON, DICKINSON AND COMPA..-5.43%68 278
    DEXCOM, INC.0.75%44 086
    HOYA CORPORATION11.14%38 371
    GE HEALTHCARE TECHNOLOGIES ..30.97%34 707
    AMERISOURCEBERGEN CORPORATI..-5.61%31 635
    ZIMMER BIOMET HOLDINGS-1.15%26 476
    WEST PHARMACEUTICAL SERVICE..42.04%24 784
    ALIGN TECHNOLOGY, INC.45.42%23 536
    More Results

    ę MarketScreener.com 2023

    Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
    The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

    Financials
    Sales 2023 3 604 M 3 877 M 3 877 M
    Net income 2023 766 M 824 M 824 M
    Net Debt 2023 535 M 575 M 575 M
    P/E ratio 2023 36,3x
    Yield 2023 0,56%
    Capitalization 27 806 M 29 911 M 29 911 M
    EV / Sales 2023 7,86x
    EV / Sales 2024 6,74x
    Nbr of Employees 11 934
    Free-Float 26,2%
    Upcoming event on SARTORIUS STEDIM BIOTECH
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus BUY
    Number of Analysts 11
    Last Close Price 301,70 €
    Average target price 395,27 €
    Spread / Average Target 31,0%
    EPS Revisions
    Managers and Directors
    Joachim Kreuzburg Chairman & Chief Executive Officer
    Oscar-Werner Reif Executive VP-Research & Development
    Anne-Marie Graffin Independent Non-Executive Director
    Susan Dexter Independent Non-Executive Director
    Pascale Boissel Independent Non-Executive Director
    Secure and increase the performance of your investments with our team of experts at your side.
    Securing my Investments
    fermer